UK-CAB 42: Diagnostics
Programme
| 09:30 – 09:50 | Registration, refreshments and expenses |
| 09:50 -10:00 | Welcome, introductions, UKCAB updates |
| 10:00 – 11:45 | Patient information security – Nathan Lea, UKCHIC |
| 10.45 – 11.15 | HIV activism at 30 – Robert James |
| 11:00 – 11.30 | Break |
| 11:30 – 12.30 | HIV Drug resistance – David Dunn, MRC CTU |
| 12:30 – 13:30 | Lunch |
| 13.30 – 14:30 | Loss to follow up study – Roger Pebody(NAM), Hilary Curtis (BHIVA audit), Brian Rice (HPA) |
| 14.30 – 15.30 | Less frequent tests, what impact on HIV care? – Dr Nashaba Matin, Mortimer Market Centre |
| 15.30 – 15.35 | Break |
| 15:35 – 16:00 | Patient reporting of medicines-related problems: feedback – Paul Clift UK-CAB AOB |
| 16.00 | Close |
Background reading:
Clive Loveday transcript:
https://ukcab.net/2002/08/resistance/
A view from the lab: interview with Professor Clive Loveday
http://i-base.info/htb/3512
Lost to care: the mystery of the disappearing patients
Loss to Follow-Up Among Adults Attending Human Immunodeficiency Virus Services in England, Wales, and Northern Ireland [PDF, 224 KB]
Adherence and retention in HIV care in resource-limited settings [PDF, 80KB]
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.